Halozyme's strategic acquisition of Evotec and innovative ENHANZE technology present growth opportunities. Click here for a ...

In a report released today, Jason Butler from JMP Securities reiterated a Buy rating on Halozyme (HALO – Research Report), with a price target ...

Not all store-bought ice cream brands are the same. Here's a list of the lowest to highest quality vanilla ice cream brands, ...

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Halozyme Therapeutics (HALO) and Amicus Therapeutics (FOLD). But which of these two companies is the ...

But we also understand that investors develop their own strategies, so we are constantly looking at the latest trends in value, growth, and momentum to find strong companies for our readers.Of these, ...

On Friday, Halozyme Therapeutics, Inc. (HALO) stock saw a decline, ending the day at $45.65 which represents a decrease of $-8.31 or -15.40% from the prior close of $53.96. The stock opened at $48.81 ...

Halozyme Therapeutics (HALO) provided an update on its non-binding proposal to acquire Evotec SE (EVO) for EUR 11.00 per share in cash, ...

The stock of German drug-discovery and development company Evotech SE jumped 4% early Monday, after Halozyme Therapeutics Inc ...

We’ll definitely do more consoles in the future, and other devices,” Microsoft Gaming CEO Phil Spencer told Rolling Stone in ...

Combination Would Create a Global Innovative Services Company with a Unique Set of Differentiated Technologies, a Deep Pipeline, and Best-in-class Industry Team Storage-Area Networking (SAN) DIEGO, ...

There simply isn’t a better gaming television on the market at a lower or even slightly higher price. The QM7 marks a roaring ...

Halozyme Therapeutics had good record of retained earnings with an average of $-330467949.14285713. Retained earnings are the ...